CS269719B1 - Platinum cytostatic - Google Patents
Platinum cytostatic Download PDFInfo
- Publication number
- CS269719B1 CS269719B1 CS8610074A CS1007486A CS269719B1 CS 269719 B1 CS269719 B1 CS 269719B1 CS 8610074 A CS8610074 A CS 8610074A CS 1007486 A CS1007486 A CS 1007486A CS 269719 B1 CS269719 B1 CS 269719B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- complex
- weight
- parts
- optionally
- platinum
- Prior art date
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 229910052697 platinum Inorganic materials 0.000 title claims abstract description 19
- 239000000824 cytostatic agent Substances 0.000 title claims abstract description 15
- 230000001085 cytostatic effect Effects 0.000 title claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000011541 reaction mixture Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 7
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229910052709 silver Inorganic materials 0.000 claims description 6
- 239000002594 sorbent Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000004332 silver Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 150000001805 chlorine compounds Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 229940093915 gynecological organic acid Drugs 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 150000001261 hydroxy acids Chemical class 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- IYWCBYFJFZCCGV-UHFFFAOYSA-N formamide;hydrate Chemical compound O.NC=O IYWCBYFJFZCCGV-UHFFFAOYSA-N 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 150000005309 metal halides Chemical class 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- UCRFYVVKDGVDJU-UHFFFAOYSA-L disodium;cyclobutane-1,1-dicarboxylate Chemical compound [Na+].[Na+].[O-]C(=O)C1(C([O-])=O)CCC1 UCRFYVVKDGVDJU-UHFFFAOYSA-L 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- XYHZRSFKDSWLHW-UHFFFAOYSA-N 1-ethoxycarbonylcyclobutane-1-carboxylic acid Chemical compound CCOC(=O)C1(C(O)=O)CCC1 XYHZRSFKDSWLHW-UHFFFAOYSA-N 0.000 description 1
- AYNSTGCNKVUQIL-UHFFFAOYSA-N C(CCCCCCCCCCC)C=1C=CC(=C(C=1)C1=NC(=CC(=C1)N(CCN(C)C)C)C1=C(C=CC(=C1)CCCCCCCCCCCC)OC)OC Chemical compound C(CCCCCCCCCCC)C=1C=CC(=C(C=1)C1=NC(=CC(=C1)N(CCN(C)C)C)C1=C(C=CC(=C1)CCCCCCCCCCCC)OC)OC AYNSTGCNKVUQIL-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002061 vacuum sublimation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Developing Agents For Electrophotography (AREA)
- Electroplating And Plating Baths Therefor (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS8610074A CS269719B1 (en) | 1986-12-29 | 1986-12-29 | Platinum cytostatic |
| FI875729A FI88165C (sv) | 1986-12-29 | 1987-12-28 | Förfarande för framställning av cis-diammin-1,1-cyklobutandikarboxylat -platina(II)komplex |
| DE8787119339T DE3771057D1 (de) | 1986-12-29 | 1987-12-29 | Platin enthaltender cytostatischer wirkstoff. |
| ES198787119339T ES2040240T3 (es) | 1986-12-29 | 1987-12-29 | Agente citostatico de platino. |
| EP87119339A EP0275559B1 (en) | 1986-12-29 | 1987-12-29 | Platinum cytostatic agent |
| AT87119339T ATE64740T1 (de) | 1986-12-29 | 1987-12-29 | Platin enthaltender cytostatischer wirkstoff. |
| JP63000051A JPS63239292A (ja) | 1986-12-29 | 1988-01-04 | 白金細胞毒性剤及びその製造方法 |
| BG82504A BG50995A1 (en) | 1986-12-29 | 1988-01-04 | Platinum cytostatic |
| IL85029A IL85029A (en) | 1986-12-29 | 1988-01-05 | Microcrystalline cis diammineplatinum(ii)complex of 1,1-cyclobutanedicarboxylic acid,its preparation and cytostatic pharmaceutical compositions containing it |
| DD31210288A DD289651A7 (de) | 1986-12-29 | 1988-01-11 | Platin-zytostatikum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS8610074A CS269719B1 (en) | 1986-12-29 | 1986-12-29 | Platinum cytostatic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS1007486A1 CS1007486A1 (en) | 1989-10-13 |
| CS269719B1 true CS269719B1 (en) | 1990-05-14 |
Family
ID=5447844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS8610074A CS269719B1 (en) | 1986-12-29 | 1986-12-29 | Platinum cytostatic |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0275559B1 (sv) |
| JP (1) | JPS63239292A (sv) |
| AT (1) | ATE64740T1 (sv) |
| BG (1) | BG50995A1 (sv) |
| CS (1) | CS269719B1 (sv) |
| DE (1) | DE3771057D1 (sv) |
| ES (1) | ES2040240T3 (sv) |
| FI (1) | FI88165C (sv) |
| IL (1) | IL85029A (sv) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8901433A (nl) * | 1989-06-06 | 1991-01-02 | Pharmachemie Bv | Carboplatinpreparaat. |
| JPH06287021A (ja) * | 1992-04-22 | 1994-10-11 | Tanaka Kikinzoku Kogyo Kk | 光学活性な白金錯化合物の光学的分割方法 |
| DE69427595T2 (de) * | 1994-02-07 | 2002-04-25 | Pliva Pharmaceutical Industry | Antitumormittel auf basis von carboplatin und herstellung desselben |
| CZ292170B6 (cs) * | 1998-08-14 | 2003-08-13 | Pliva-Lachema A.S. | Farmaceutická kompozice s protinádorovým účinkem na bázi carboplatiny |
| CN1121380C (zh) | 2000-03-03 | 2003-09-17 | 北京兴大豪斯科技有限公司 | 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物 |
| DE10306761B9 (de) * | 2003-02-17 | 2004-12-23 | Völkl, Klaus Peter, Dr. | Verfahren zur Herstellung von sterilen pharmazeutischen Wirkstoffen |
| HRP20211466T1 (hr) | 2015-12-09 | 2021-12-24 | Medizinische Universität Wien | Spojevi platine funkcionalizirani monomaleimidom, namijenjeni terapiji raka |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH605550A5 (sv) * | 1972-06-08 | 1978-09-29 | Research Corp | |
| US4302446A (en) * | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
| ES8801168A1 (es) * | 1984-11-02 | 1987-02-16 | Johnson Matthey Plc | Procedimiento para la obtencion de un compuesto de platino para utilizar en quimioterapia del cancer. |
-
1986
- 1986-12-29 CS CS8610074A patent/CS269719B1/cs unknown
-
1987
- 1987-12-28 FI FI875729A patent/FI88165C/sv not_active IP Right Cessation
- 1987-12-29 ES ES198787119339T patent/ES2040240T3/es not_active Expired - Lifetime
- 1987-12-29 AT AT87119339T patent/ATE64740T1/de not_active IP Right Cessation
- 1987-12-29 DE DE8787119339T patent/DE3771057D1/de not_active Expired - Fee Related
- 1987-12-29 EP EP87119339A patent/EP0275559B1/en not_active Expired - Lifetime
-
1988
- 1988-01-04 JP JP63000051A patent/JPS63239292A/ja active Pending
- 1988-01-04 BG BG82504A patent/BG50995A1/xx unknown
- 1988-01-05 IL IL85029A patent/IL85029A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI88165B (fi) | 1992-12-31 |
| IL85029A0 (en) | 1988-06-30 |
| ES2040240T3 (es) | 1993-10-16 |
| EP0275559A1 (en) | 1988-07-27 |
| IL85029A (en) | 1992-06-21 |
| FI88165C (sv) | 1993-04-13 |
| ATE64740T1 (de) | 1991-07-15 |
| EP0275559B1 (en) | 1991-06-26 |
| CS1007486A1 (en) | 1989-10-13 |
| BG50995A1 (en) | 1993-01-15 |
| FI875729A (fi) | 1988-06-30 |
| JPS63239292A (ja) | 1988-10-05 |
| DE3771057D1 (de) | 1991-08-01 |
| FI875729A0 (fi) | 1987-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8211940B2 (en) | Oxaliplatin active substance with a very low content of oxalic acid | |
| EP1925621A1 (en) | Crystalline forms of zoledronic acid | |
| CN111171080B (zh) | 细胞及活体内自催化合成的高效低毒抗癌化合物及其合成方法 | |
| WO2018214886A1 (zh) | 一种氘代azd9291的晶型、制备方法及用途 | |
| KR20020095022A (ko) | 이중 디카르복실산 디아미노플라틴 착체의 항종양 유도체, 그의 제조방법, 그것을 함유하는 약학조성물 및 그 유도체의 적용 | |
| JP3579423B2 (ja) | ロバプラチナ三水和物 | |
| CS269719B1 (en) | Platinum cytostatic | |
| JP2919867B2 (ja) | 抗腫瘍剤 | |
| EP0115929A1 (en) | Novel organic platinum complex and process for the preparation thereof | |
| RU2203901C2 (ru) | Комплексные соединения платины, способы их получения, фармацевтическая композиция | |
| JPH02500745A (ja) | 抗腫瘍活性をもつ１，２‐ジアミノシクロヘキサン‐プラチナ錯体 | |
| US4739087A (en) | Antineoplastic platinum complexes | |
| RU2054286C1 (ru) | Платиновый цитостатик и способ его получения | |
| US4416878A (en) | [8-(Dialkylamino alkoxy)-caffeine]-platinum complex compounds and pharmaceutical products containing the same | |
| CN102786458B (zh) | 吡咯甲酰胺衍生物、其制备方法和用途 | |
| CN101863927B (zh) | 抗肿瘤药物钯配合物 | |
| EP0302181B1 (en) | A process for preparing platinum-(ii)-cis-dichlorobis-(trishydroxymethylphosphine) | |
| JPWO2021080019A1 (ja) | 新規有機ゲルマニウム化合物 | |
| JPH03500532A (ja) | 白金系医薬品 | |
| US5723487A (en) | Preparation of a product for treatment of colagen-related disorders | |
| JPH04112833A (ja) | 抗腫瘍剤 | |
| JPS6310725A (ja) | 新規白金錯体化合物を有効成分として含有する制癌剤 | |
| JPH02212497A (ja) | 新規白金錯体及びその製法 | |
| JPS6310724A (ja) | 新規白金錯体を有効成分として含有する制癌剤 | |
| FR2557572A1 (fr) | Complexe bis(trihydroxo) du platine (ii), sa preparation et son application therapeutique |